Our work illuminates actionable metabolic features driven by the TFE3 fusion in tRCC that are distinct from other RCC subtypes, offering hope that molecularly-directed therapies can be advanced to specifically target the biology of this aggressive subtype of kidney cancer. This evidence concerns the gene TFE3 and renal cell carcinoma.